Does BPC-157 heal tendon and ligament injuries in humans?
BPC-157 is often promoted as a recovery peptide for tendon, ligament and gym injuries.
Simple answer
No strong human evidence shows that BPC-157 heals tendon or ligament injuries. Most support is animal, cell or mechanism-based, and internet recovery claims should not be treated as proven clinical benefit. The safer reading is: do not treat social media or clinic marketing as proof, and do not use this page for medical decisions.
Bottom line at a glance
- What does evidence mean?
- Interesting science, but not proof it works in people.
- Why risk matters
- Do not use this page for dosing, sourcing or self-administration decisions.
- Approval status
- Do not read online claims as FDA approval.
Last checked: Jun 27, 2026
What people claim
The leap is from repair signals in models to broad human sports-injury recovery claims.
What we know
- Preclinical work has explored tissue-repair mechanisms, but that does not establish human tendon or ligament healing.
- Human evidence remains limited and does not support broad recovery claims for healthy consumers.
- Regulatory and quality questions matter because products discussed online may not be approved medicines.
What we do not know
- It does not prove BPC-157 heals tendons in humans.
- It does not prove consumer products are pure, sterile or legal for a claimed use.
- It does not prove anti-aging, gym recovery or broad injury-repair claims.
What should you do with this information?
- Use it to ask better questions, not to self-experiment.
- Do not use this page for dosing, sourcing, stacking or self-administration decisions.
- Speak with a qualified clinician before acting on high-risk claims.
What not to do
- Do not self-administer based on this page.
- Do not use this page for dosing, sourcing, stacking, cycle planning or injection instructions.
- Do not start, stop or combine drugs, peptides, supplements or experimental interventions without a qualified clinician.
Questions to ask a qualified clinician
- What exact medical indication is being discussed, and is it approved for that use?
- What human evidence exists for my situation, not just animals, cells or biomarkers?
- What monitoring, contraindications and interaction questions matter before any decision?
- What outcome would show benefit, and what outcome would show harm or no effect?
Want the deeper version?
Open these sections if you want the source detail, regulatory context and expert notes.
Show the evidenceSources, study type and where the claim gets weaker.+
A musculoskeletal review focused on the promise and risk gap around BPC-157 rather than treating injury recovery as settled.
- Publisher
- Current Reviews in Musculoskeletal Medicine
- Accessed
- Jun 27, 2026
- Study type
- Systematic Review
Limitations: Narrative reviews synthesize existing literature; they do not replace controlled human injury trials.
Systematic review of BPC-157 in orthopaedic sports medicine, useful for explaining why interest exists and where human evidence is thin.
- Publisher
- HSS Journal
- Accessed
- Jun 27, 2026
- Study type
- Systematic Review
Limitations: A review can map the evidence base but cannot establish benefit where underlying human trials are limited.
Review of BPC-157 and repair biology; useful for why the claim is plausible enough to study.
- Publisher
- Pharmaceuticals
- Accessed
- Jun 27, 2026
- Study type
- Systematic Review
Limitations: Much of the evidence discussed is preclinical or mechanism-heavy, not proof of consumer injury recovery.
Physician-facing primer showing why sports-medicine clinicians are seeing more peptide questions.
- Publisher
- American Journal of Sports Medicine
- Accessed
- Jun 27, 2026
- Study type
- Systematic Review
Limitations: A clinician primer is contextual; it is not a protocol or endorsement of unsupervised use.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness or quality before marketing.
- Publisher
- FDA
- Accessed
- Jun 27, 2026
- Study type
- Regulatory Document
Limitations: Regulatory language is product-, jurisdiction- and use-specific. Always verify the current official page before relying on it.
FDA safety-risk context for nominated bulk substances used in compounding, relevant when internet peptide claims imply compounding equals approval.
- Publisher
- FDA
- Accessed
- Jun 27, 2026
- Study type
- Regulatory Document
Limitations: Regulatory language is product-, jurisdiction- and use-specific. Always verify the current official page before relying on it.
Regulatory
BPC-157: Experimental Peptide Prohibited
USADA frames BPC-157 as an experimental peptide prohibited under WADA's S0 unapproved-substances category.
- Publisher
- USADA
- Accessed
- Jun 27, 2026
- Study type
- Regulatory Document
Limitations: Anti-doping guidance is not a medical evidence review, but it is highly relevant for athlete risk and prohibited-substance context.
Background
ClinicalTrials.gov search: BPC-157
Shows whether registered human studies exist and what outcomes they are actually testing.
- Publisher
- ClinicalTrials.gov
- Accessed
- Jun 27, 2026
- Study type
- Regulatory Document
Limitations: Trial registration does not prove benefit; it shows a study has been registered.
FDA compounding safety-risk context is not approval for tendon recovery or anti-aging claims.
- Publisher
- FDA
- Accessed
- Jun 27, 2026
- Study type
- Regulatory Document
Limitations: Regulatory status is use-specific and can change; readers should verify current labels and official notices.
Weakest link in the claim
- Testimonials and clinic claims often skip the gap between model systems and controlled human outcomes.
- Product identity, sterility and supervision are separate risks from whether a mechanism is plausible.
Show regulatory detailApproval status is use-specific. Internet claims may not match reviewed uses.+
Show expert notesWhat would change our mind, money trail and related claims.+
What would change our mind
- Well-designed human randomized trials with injury-specific endpoints.
- Clear regulatory status for a defined product and use.
- Independent replication showing meaningful recovery outcomes, not only biomarkers.
Money trail
Who might profit:Clinic incentiveCommercial context does not automatically make a claim false, but it changes how carefully the claim should be read.
- BPC-157 is commonly promoted by clinics and online sellers, so commercial incentive is a meaningful part of the claim context.
- A recovery claim may be attached to a product or service even when the original evidence is narrower.
FAQs
Does this page give a protocol?
No. LHN claim checks explain evidence, risk, regulatory status and source context. They do not provide personal medical instructions.
Is BPC-157 FDA-approved for tendon healing?
No. LHN currently treats tendon-healing claims as unproven and not approved for that use.
Related claims
peptides
Does TB-500 speed injury recovery?
TB-500 injury-recovery claims are not supported by strong human clinical evidence.
Longevity drugs
Does rapamycin slow aging in humans?
Rapamycin has unusually strong aging-biology interest, but it is not proven to slow human aging or extend lifespan in healthy adults.
Related guides
Get the weekly longevity evidence briefing.
One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.
No protocols. No miracle claims. No spam.